#Sweden #Semaglutide #Orexo #AmorphOX #Uppsala

Orexo's AmorphOX Technology: A Game Changer for Intranasal GLP-1 Medications

In a recent advancement in drug delivery technology, Orexo AB has showcased its innovative AmorphOX platform's potential to create intranasal formulations of glucagon-like peptide-1 (GLP-1) medications. This novel approach could significantly enhance how these critical drugs—currently used to manage type 2 diabetes and obesity—are delivered and administered.

Understanding AmorphOX Technology

Orexo's AmorphOX technology is a proprietary drug delivery platform that utilizes a unique combination of drug particles and carrier materials to create stabilized powders. These particles are amorphous, which allows for rapid dissolution and excellent bioavailability. This property is especially crucial for large biologics, such as peptides and proteins, including semaglutide.

Semaglutide, a GLP-1 receptor agonist, is currently available in both oral tablets and injectable forms. However, the oral route presents challenges with variable bioavailability, as it can degrade in the gastrointestinal tract. In contrast, injectable options require refrigeration and come with the inconvenience of needle use. Orexo's AmorphOX technology seeks to address these issues by providing a needle-free, intranasal alternative.

The Promising Study Results

Orexo recently completed a preclinical pharmacokinetic in-vivo study comparing three formulations of powder-based semaglutide delivered intranasally via AmorphOX technology with the oral and injectable forms of the medication. The results were revealing: the intranasal formulations exhibited significantly higher plasma concentrations and bioavailability than the oral tablet. Specifically, two formulations showed a remarkable sevenfold increase in plasma values compared to Rybelsus® (the oral form), while maintaining lower variability in plasma concentration.

At a time when patient adherence is vital, these advancements suggest that intranasal delivery via AmorphOX may lead to better patient outcomes. This approach could eliminate the need for refrigeration and reduce the frequency of dosing schedules, potentially making treatment regimens simpler and more manageable for patients.

Building on Success

Robert Rönn, Orexo’s Senior Vice President and Head of Research and Development, expressed enthusiasm about the findings. He emphasized that the successful formulation of large peptides like semaglutide using AmorphOX could pave the way for effectively creating other GLP-1 receptor agonists and potentially expanding to vaccines. This aligns with Orexo's strategic vision to focus on larger molecules, enhancing the range of treatments available via innovative delivery methods.

The study's positive outcomes not only reinforce the viability of intranasal formulations but also position Orexo to establish strategic partnerships aimed at further advancing the use of AmorphOX technology. By developing intranasal options, Orexo can contribute significantly to the pharmaceutical landscape, promoting easier access to effective treatments for chronic conditions like diabetes.

A Future of Enhanced Treatment Options

As the healthcare industry continues to evolve, technologies like Orexo's AmorphOX serve as critical building blocks for the future of medicinal delivery. The ability to offer options that require no needles, reduced dosing frequency, and no need for refrigeration is particularly appealing to patients who may struggle with adherence to more conventional treatment methods.

In conclusion, Orexo's advancements in intranasal GLP-1 medications signify a noteworthy shift towards more patient-centered drug delivery methods. As the company looks to collaborate with industry partners, the possibilities for improved treatment solutions become increasingly exciting. For healthcare providers and patients alike, the implications of these developments are profound, potentially transforming how chronic conditions are managed moving forward.

For more information about Orexo and their innovative approaches to drug development, visit www.orexo.com.